CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia

被引：0

作者：

Jing, P. ^{[1
,2
]}

Niu, Q. ^{[2
]}

Deng, B. ^{[3
]}

Liu, S. ^{[1
]}

Wu, T. ^{[4
]}

Gao, Z. ^{[4
]}

Chang, A. H. ^{[5
]}

Feng, X. ^{[2
]}

Tong, C. ^{[1
]}

机构：

[1] Beijing Boren Hosp, Dept Hematol, Beijing, Peoples R China

[2] Inst Hematol & Hosp Blood Dis, Tianjin, Peoples R China

[3] Beijing Boren Hosp, Cytol Lab, Beijing, Peoples R China

[4] Beijing Boren Hosp, Dept Bone Marrow Transplantat, Beijing, Peoples R China

[5] Tongji Univ, Sch Med, Clin Translat Res Ctr, Shanghai, Peoples R China

来源：

EUROPEAN JOURNAL OF IMMUNOLOGY | 2019年 / 49卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

P2287

引用

页码：1723 / 1723

页数：1

共 50 条

[21] Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
Sining Liu
Xinyue Zhang
Haiping Dai
Wei Cui
Jia Yin
Zheng Li
Xiao Yang
Chunxiu Yang
Shengli Xue
Huiying Qiu
Miao Miao
Suning Chen
Zhengming Jin
Chengcheng Fu
Caixia Li
Aining Sun
Yue Han
Ying Wang
Lei Yu
Depei Wu
Qingya Cui
Xiaowen Tang
Blood Cancer Journal, 13
[22] Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
Liu, Sining
Zhang, Xinyue
Dai, Haiping
Cui, Wei
Yin, Jia
Li, Zheng
Yang, Xiao
Yang, Chunxiu
Xue, Shengli
Qiu, Huiying
Miao, Miao
Chen, Suning
Jin, Zhengming
Fu, Chengcheng
Li, Caixia
Sun, Aining
Han, Yue
Wang, Ying
Yu, Lei
Wu, Depei
Cui, Qingya
Tang, Xiaowen
BLOOD CANCER JOURNAL, 2023, 13 (01)
[23] CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial
Cordoba, Shaun
Onuoha, Shimobi
Thomas, Simon
Pignataro, Daniela Soriano
Hough, Rachael
Ghorashian, Sara
Vora, Ajay
Bonney, Denise
Veys, Paul
Rao, Kanchan
Lucchini, Giovanna
Chiesa, Robert
Chu, Jan
Clark, Liz
Fung, Mei Mei
Smith, Koval
Peticone, Carlotta
Al-Hajj, Muhammad
Baldan, Vania
Ferrari, Mathieu
Srivastava, Saket
Jha, Ram
Vargas, Frederick Arce
Duffy, Kevin
Day, William
Virgo, Paul
Wheeler, Lucy
Hancock, Jeremy
Farzaneh, Farzin
Domning, Sabine
Zhang, Yiyun
Khokhar, Nushmia Z.
Peddareddigari, Vijay G. R.
Wynn, Robert
Pule, Martin
Amrolia, Persis J.
NATURE MEDICINE, 2021, 27 (10) : 1797 - +
[24] CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial
Shaun Cordoba
Shimobi Onuoha
Simon Thomas
Daniela Soriano Pignataro
Rachael Hough
Sara Ghorashian
Ajay Vora
Denise Bonney
Paul Veys
Kanchan Rao
Giovanna Lucchini
Robert Chiesa
Jan Chu
Liz Clark
Mei Mei Fung
Koval Smith
Carlotta Peticone
Muhammad Al-Hajj
Vania Baldan
Mathieu Ferrari
Saket Srivastava
Ram Jha
Frederick Arce Vargas
Kevin Duffy
William Day
Paul Virgo
Lucy Wheeler
Jeremy Hancock
Farzin Farzaneh
Sabine Domning
Yiyun Zhang
Nushmia Z. Khokhar
Vijay G. R. Peddareddigari
Robert Wynn
Martin Pule
Persis J. Amrolia
Nature Medicine, 2021, 27 : 1797 - 1805
[25] Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma
Huang, Lefu
Li, Jingjing
Yang, Junfang
Zhang, Xian
Zhang, Min
He, Jiujiang
Zhang, Gailing
Li, Wenqian
Wang, Hui
Li, Jianqiang
Lu, Peihua
CELLS, 2022, 11 (24)
[26] CD22-Directed CAR T-Cell Therapy Mediates Durable Complete Responses in Adults with Relapsed or Refractory Large B-Cell Lymphoma after Failure of CD19-Directed CAR T-Cell Therapy and High Response Rates in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Baird, John H.
Frank, Matthew J.
Craig, Juliana
Patel, Shabnum
Spiegel, Jay Y.
Sahaf, Bita
Younes, Sheren F.
Oak, Jean S.
Natkunam, Yasodha
Ehlinger, Zachary
Reynolds, Warren D.
Arai, Sally
Johnston, Laura J.
Lowsky, Robert
Negrin, Robert S.
Rezvani, Andrew R.
Shiraz, Parveen
Sidana, Surbhi
Weng, Wen-Kai
Schultz, Liora M.
Ramakrishna, Sneha
Davis, Kara L.
Feldman, Steven A.
Mackall, Crystal L.
Miklos, David B.
Muffly, Lori S.
BLOOD, 2020, 136
[27] CD19/CD22 chimeric antigen receptor T-cell therapy for refractory acute B-cell lymphoblastic leukemia with FLT3-ITD mutations
Aiyun Jin
Jingjing Feng
Guoqing Wei
Wenjun Wu
Luxin Yang
Huijun Xu
Yanlei Zhang
Jiazhen Cui
Alex Hongsheng Chang
Yongxian Hu
He Huang
Bone Marrow Transplantation, 2020, 55 : 717 - 721
[28] CD19/CD22 chimeric antigen receptor T-cell therapy for refractory acute B-cell lymphoblastic leukemia with FLT3-ITD mutations
Jin, Aiyun
Feng, Jingjing
Wei, Guoqing
Wu, Wenjun
Yang, Luxin
Xu, Huijun
Zhang, Yanlei
Cui, Jiazhen
Chang, Alex Hongsheng
Hu, Yongxian
Huang, He
BONE MARROW TRANSPLANTATION, 2020, 55 (04) : 717 - 721
[29] Nelarabine Combination Therapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Lymphoma/Leukemia
Shimony, Shai
Liu, Yiwen
Valtis, Yannis K.
Paolino, Jonathan D.
Place, Andrew E.
Brunner, Andrew M.
Weeks, Lachelle D.
Silverman, Lewis B.
Vrooman, Lynda M.
Neuberg, Donna S.
Stone, Richard M.
DeAngelo, Daniel J.
Luskin, Marlise R.
BLOOD, 2022, 140 : 8989 - 8990
[30] Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia
Shimony, Shai
Liu, Yiwen
Valtis, Yannis K.
Paolino, Jonathan D.
Place, Andrew E.
Brunner, Andrew M.
Weeks, Lachelle D.
Silverman, Lewis B.
Vrooman, Lynda M.
Neuberg, Donna S.
Stone, Richard M.
DeAngelo, Daniel J.
Luskin, Marlise R.
BLOOD ADVANCES, 2023, 7 (07) : 1092 - 1102

← 1 2 3 4 5 →